Mark Foley is CEO of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors of Glaukos (GKOS) and as chairman of the board for ULab. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame in 1987 and is a named inventor on 17 patent applications.
What is Mark J. Foley's net worth?
The estimated net worth of Mark J. Foley is at least $120,920.80 as of February 23rd, 2024. Mr. Foley owns 33,220 shares of Revance Therapeutics stock worth more than $120,921 as of April 23rd. This net worth evaluation does not reflect any other investments that Mr. Foley may own. Additionally, Mr. Foley receives a salary of $1,260,000.00 as CEO at Revance Therapeutics. Learn More about Mark J. Foley's net worth.
How old is Mark J. Foley?
What is Mark J. Foley's salary?
How do I contact Mark J. Foley?
Has Mark J. Foley been buying or selling shares of Revance Therapeutics?
Mark J. Foley has not been actively trading shares of Revance Therapeutics over the course of the past ninety days. Most recently, Mark J. Foley sold 26,279 shares of the business's stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $22.57, for a transaction totalling $593,117.03. Following the completion of the sale, the chief executive officer now directly owns 840,375 shares of the company's stock, valued at $18,967,263.75. Learn More on Mark J. Foley's trading history.
Who are Revance Therapeutics' active insiders?
Are insiders buying or selling shares of Revance Therapeutics?
In the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 264,745 shares worth more than $7,128,621.54. The most recent insider tranaction occured on April, 16th when insider Erica Jordan sold 2,392 shares worth more than $9,089.60. Insiders at Revance Therapeutics own 3.5% of the company.
Learn More about insider trades at Revance Therapeutics. Information on this page was last updated on 4/16/2024.
